Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study includes RA patients in pregnancy, who are using different treatment regimens，including prednisone, hydroxychloroquine, and/or TNF inhibitors. The maternal disease activity, pregnancy outcomes, maternal and fetal safety are assessing during the trimester of pregnancy. The effects of different therapies and risk factors for adverse pregnancy outcomes will be analysis.
To study the risk factors of poor pregnancy outcomes in RA patients, and evaluate impact of different therapies on the maternal and fetal health.
The follow-up study will be scheduled every 4 weeks from confirmed pregnancy until delivery, records the disease activity of RA, pregnancy outcome and safety with the help of the "smart disease management system (SSDM)" and face-to-face consultations.
The effects of different therapies on maternal and fetal will be valued
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patients not using TNF inhibitors(TNFi) | The cohort includes the RA patients in pregnancy. Drug: Hydroxychloroquine(HCQ)，200mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Drug: Prednisone(Pred)，5-30mg, po, once per day (qd) prescribed at the beginning and adjusted due to patient response. |
| |
| patients using TNF inhibitor (TNFi) | The cohort includes the RA patients in pregnancy. Drug: Hydroxychloroquine(HCQ)，200mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Drug: Prednisone(Pred)，5-30mg, po, once per day (qd) prescribed at the beginning and adjusted due to patient response. Drug: TNFi ,such as Certolizumab Pegol (Cimzia)，200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Prednisone | Drug | 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response |
|
| Measure | Description | Time Frame |
|---|---|---|
| The percentage of patients who achieve clinical remission using DAS28-CRP | The percentage of patients whose DAS28 achieve remission（DAS28-CRP≤ 2.6）and Low Disease Activity (DAS28-CRP ≤3.2) . | through study completion, an average of 10 months |
| Measure | Description | Time Frame |
|---|---|---|
| Early fetal loss | Spontaneous pregnancy loss within 10 weeks of gestation | within 10 weeks of gestation |
| Late fetal loss | Spontaneous pregnancy loss after 10 weeks of gestation |
Not provided
Inclusion Criteria:
- 1.Age between 20 and 45 years old.
2.Diagnosis of RA: Approved by the American College of Rheumatology and the European League Against Rheumatism in 2010.
Involved joints 1 large joint (0 points) 2-10 large joints (1 point) 1-3 small joints (with or without large joints) (2 points) 4-10 small joints (with or without large joints) (3 points) more than 10 small joints (at least one small joint) (5 points)
Serological indicators RF and ACPA negative (0 points) RF and ACPA, at least one of which is low titer positive. (2 points) RF and ACPA with at least one high titer positive (3 points)
Acute chronotropic reactants Both CRP and ESR normal (0 points) Abnormal CRP or ESR (1 point)
Duration of synovitis <6 weeks (0 points)
≥6 weeks (1 point)
3.Voluntary participation in this study, willingness to administer medication and follow up according to the treatment plan, and signing of an informed consent form.
Exclusion Criteria:
Women who meet any of the following criteria will be excluded from the study
Any known etiology of previous pregnancy loss
Any active infection, including bacterial, alisla virus (VZV), human immunodeficiency virus (HIV), human papillomavirus (HPV), syphilis, tuberculosis, fungal infections, etc.
Hypersensitivity to prednisone, hydroxychloroquine, low molecular weight heparin or aspirin
History of the following diseases.
Not provided
Not provided
female with pregnance in accordance with the diagnostic criteria of Rheumatoid arthritis in 2010.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Qiang Shu | Contact | 0086-0531-82169654 | shuqiang@sdu.edu.cn | |
| Bingbing Ren | Contact | +8618765361979 | sdrenbingbing@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Xiaoyun Yang | Qilu Hospital of Shandong University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Qilu Hospital | Recruiting | Jinan | Shandong | Shandong | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D011241 | Prednisone |
| C036266 | prednylidene |
| D006886 | Hydroxychloroquine |
| D000068582 | Certolizumab Pegol |
| ID | Term |
|---|---|
| D011244 | Pregnadienediols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 |
Not provided
Not provided
Not provided
Not provided
Not provided
Early, intermediate and late peripheral blood specimens、cord blood specimens、placental tissue
|
| Hydroxychloroquine | Drug | 200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response. |
|
|
| CertolizumabPegol injection | Drug | 200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response. |
|
|
| after 10 weeks of gestation |
| Still birth | Spontaneous pregnancy loss after 10 weeks of gestation. | after 10 weeks of gestation |
| Preterm delivery | Live birth before 37 weeks of gestation. | between 28 and 37 weeks of gestation |
| Low-weight birth | newborns with low weight (<2500g) | after 28 weeks of gestation |
| Premature rupture of membranes | the number of participants complicated with placental abruption | after 28 weeks of gestation |
| Placental abruption | the number of participants complicated with placental abruption | after 28 weeks of gestation |
| Fetal growth retardation (FGR) | weight below the 10th percentile for the gestational age | after 12 weeks of gestation |
| Number of participants with low amniotic fluid during pregnancy | the number of participants whose B-ultrasound indicates low amniotic fluid during pregnancy | after 12 weeks of gestation |
| Number of participants with abnormal S / D values during pregnancy | the number of participants whose B-ultrasound indicates abnormal S / D values during pregnancy | after 12 weeks of gestation |
| Number of participants with placental hematoma during pregnancy | the number of participants whose B-ultrasound indicates placental hematoma during pregnancy | during pregnancy |
| Eclampsia | New-onset hypertension after 20 weeks of gestation, with or without proteinuria > 300mg/24h, with or without any organ damage with seizures | after 20 weeks of gestation |
| Gestational diabetes | the number of participants who were diagnosed with gestational diabetes | through study completion, an average of 10 months |
| Gestational hypertension | the number of participants who were diagnosed with gestational hypertension | through study completion, an average of 10 months |
| Number of participants with placental infarction | the number of participants whose placenta with infarction. | at delivery |
| Change From Baseline in C-reactive Protein (CRP) | Change from Baseline in C-reactive Protein (CRP), CRP will be measured with blood samples. | through study completion, an average of 10 months |
| Erythrocyte Sedimentation Rate (ESR) | Change from Baseline in Erythrocyte Sedimentation Rate (ESR), ESR will be measured with blood samples. | through study completion, an average of 10 months |
| Live birth rate | Percentage of all patients that lead to live birth after 28 weeks of gestation | After 28 weeks of gestation |
| Change from baseline Simplified Disease Activity Index (SDAI) | SDAI score exceeding 26 is considered high disease activity; 11 \ | through study completion, an average of 10 months |
| Change from baseline Clinical Disease Activity Index (CDAI) | CDAI > 22 is considered high disease activity; 10 \ | through study completion, an average of 10 months |
| swollen joint number (SW28) | SW28 means the number of joints with swelling counted in 28 synovial joints, including proximal interphalangeal joints (10 joints), metacarpophalangeal joints (10), wrists (2), elbows (2), shoulders (2) and knees (2) bilateral. | through study completion, an average of 10 months |
| tenderness joint number (T28) | T28 means the number of joints with tenderness upon touching counted in 28 synovial joints, including proximal interphalangeal joints (10 joints), metacarpophalangeal joints (10), wrists (2), elbows (2), shoulders (2) and knees (2) bilateral. | through study completion, an average of 10 months |
| patient global assessment(PGA) | patient global assessment(PGA) | through study completion, an average of 10 months |
| Health Assessment Questionnaire (HAQ) | Health Assessment Questionnaire (HAQ) | through study completion, an average of 10 months |
| Percentage of patients achieving Boolean remission | Clinical remission was defined when the number of swollen joints ≤1, the number of painful joints ≤1, CRP ≤1 mg/dl and the patient's overall score of the disease ≤1 were also satisfied. | through study completion, an average of 10 months |
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D002738 | Chloroquine |
| D000634 | Aminoquinolines |
| D011804 | Quinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D011092 | Polyethylene Glycols |
| D011108 | Polymers |
| D046911 | Macromolecular Substances |
| D007140 | Immunoglobulin Fab Fragments |
| D007128 | Immunoglobulin Fragments |
| D010446 | Peptide Fragments |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |